Provided by Tiger Trade Technology Pte. Ltd.

Alnylam Pharmaceuticals

236.22
+6.923.02%
Post-market: 236.480.2586+0.11%19:58 EDT
Volume:1.91M
Turnover:449.27M
Market Cap:31.52B
PE:42.04
High:238.97
Open:228.88
Low:228.34
Close:229.30
52wk High:495.55
52wk Low:197.81
Shares:133.43M
Float Shares:133.16M
Volume Ratio:1.16
T/O Rate:1.43%
Dividend:- -
Dividend Rate:- -
EPS(TTM):5.62
EPS(LYR):2.33
ROE:96.55%
ROA:12.34%
PB:23.28
PE(LYR):101.38

Loading ...

Alnylam falls -25.5%

TIPRANKS
·
Jul 30

Movement Alert|Alnylam Pharmaceuticals Falls 20.29% in Regular Trading, Q2 Revenue Misses Estimates as Full-Year Guidance Cut

Market Focus
·
Jul 30

Alnylam Pharmaceuticals' Q2 Adjusted EPS, Revenue Rise; Cuts 2026 Net Product Revenue Guidance; Shares Tumble Pre-Bell

MT Newswires Live
·
Jul 30

Alnylam Pharmaceuticals Shares Down 26% Premarket After Co Trims 2026 Product Sales Forecast

THOMSON REUTERS
·
Jul 30

Alnylam Slips After Trimming 2026 Product Sales Forecast

Reuters
·
Jul 30

Alnylam Q2 Revenue Rises 67% on Increased Demand for Amvuttra

Reuters
·
Jul 30

Alnylam Q2 GAAP Net Income Swings to USD 164.49 Million; Revenue Rises 67% to USD 1.29 Billion vs Q2 FY25

Reuters
·
Jul 30

GUIDANCE: (ALNY) Alnylam Pharmaceuticals Expects 2026 Total Net Product Revenue Range $4.70B - $5.10B

MT Newswires Live
·
Jul 30

Movement Alert|Alnylam Pharmaceuticals Falls 7.45% in Pre-Market Trading, Selling Pressure on Q2 Earnings Release Day

Market Focus
·
Jul 30

Stock Track | Alnylam Pharmaceuticals Plunges 7.45% in Pre-market as Q2 Revenue Misses Estimates

Stock Track
·
Jul 30

Alnylam Pharmaceuticals Q2 Adj. EPS $1.84 Beats $1.55 Estimate, Sales $1.291B Miss $1.323B Estimate

Benzinga Earnings
·
Jul 30

Alnylam Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Period Progress

THOMSON REUTERS
·
Jul 30

Alnylam Pharmaceuticals Q2 Operating Income USD 231.441 Million

THOMSON REUTERS
·
Jul 30

Alnylam Pharmaceuticals Q2 Adjusted EPS USD 1.84 VS. Ibes Estimate USD 1.55

THOMSON REUTERS
·
Jul 30

Earning Preview: Alnylam Pharmaceuticals Q2 revenue is expected to increase by 101%, and institutional views are mostly bullish

Earnings Agent
·
Jul 24

Alnylam Pharmaceuticals is Maintained at Overweight by JP Morgan

Dow Jones
·
Jul 22

Alnylam Pharma (ALNY) Gets a Buy from Oppenheimer

TIPRANKS
·
Jul 22

U.s. Research Roundup-danaher, Gm, Msci

Reuters
·
Jul 22

Alnylam Pharmaceuticals (ALNY) Could Be 39% Below Fair Value As Alzheimer’s Pipeline Progresses

Simply Wall St.
·
Jul 18

Movement Alert|Alnylam Pharmaceuticals Falls 5.04% in Regular Trading, Trading at $268.73

Market Focus
·
Jul 18